In an interview with Targeted Oncology, Alejandro Rios Hoyo, associate research scientist at Yale School of Medicine, discusses how a new recent analysis of hormone receptor HR+, HER2-negative breast cancers demonstrated that these cancers closely resemble triple-negative breast cancers in both molecular features and clinical behavior, guiding new therapies and treatment plans. Read more here: https://lnkd.in/gakHKE9M #Agendia #IlluminatingTumorBiology #BreastCancer
Agendia
生物技术
Irvine,CA 19,676 位关注者
MammaPrint? + BluePrint? provides you with actionable insights throughout your patient’s breast cancer journey.
关于我们
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint?, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint?, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint? and BluePrint? provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/
- 网站
-
https://www.agendia.com
Agendia的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Irvine,CA
- 类型
- 私人持股
- 创立
- 2003
地点
-
主要
22 Morgan
US,CA,Irvine,92618
Agendia员工
-
Stephanie Bywater
Biotech and Healthcare Compliance Executive | Making compliance requirements easy to understand and operationalize | Helping the healers focus on…
-
Wilco van der Lugt
Senior Sales Director EMEA & APAC at Agendia
-
David Devigne
PharmD, PhD in Entrepreneurial Finance | Investment Director Life Sciences at Korys
-
Michael Mott
Freelance Web/Design/Communications Consultant
动态
-
In a recent report by NPJ Precision Oncology, a unique case is presented where a young woman was diagnosed with locally advanced, inflammatory HR+ HER2? breast cancer. BluePrint testing revealed a basal-like (TNBC) subtype—despite strong ER expression on IHC. MammaPrint testing on the patient also revealed a very high risk of recurrence. By treating the patient with a TNBC-based neoadjuvant protocol, the patient achieved a complete response and remains disease-free after two years. Read the full case report: https://lnkd.in/gSsqpmSe #Agendia #IlluminatingTumorBiology #BreastCancer
-
The SWOG S2206 is a Phase III Trial examining the effectiveness of neoadjuvant immunotherapy in High-Risk HR+ breast cancer patients. This trial, sponsored by the National Cancer Institute (NCI) and led by SWOG Cancer Research Network, will utilize Agendia’s MammaPrint? breast cancer recurrence test to identify patients most likely to benefit from immunotherapy. The insights gained may provide new therapeutic options for women with high-risk HR+ breast cancer. Learn more: https://lnkd.in/dFQ8iMd4 #agendia #IlluminatingTumorBiology #ClinicalTrials #BreastCancerResearch #SWOGS2206
-
-
Our founder Laura van 't Veer was recently awarded the William L. McGuire Memorial Lecture Award at SABCS 2024. She was honored for her pioneering contributions to risk stratification, subtyping, and enhancing early breast cancer treatment through the development of MammaPrint and her leadership in the I-SPY 2 trials. Learn more about Laura and her groundbreaking work in this interview by SABCS program director Kate Lathrop, MD: https://lnkd.in/giJ4gwT9 #Agendia #IlluminatingTumorBiology #BreastCancer #SABCS2024
-
-
We’re excited to attend the Society of Surgical Oncology 2025 Conference in Tampa and engage with top surgical oncologists working in breast cancer care. Join us as we discuss the power of MammaPrint & BluePrint in guiding treatment decisions. Make sure to visit us at booth 132, see you there! https://lnkd.in/g-icKT3b #Agendia #illuminatingtumorbiology #SSO2025 Society of Surgical Oncology
-
Navigating biomarker testing in early-stage breast cancer can be overwhelming for you and your patients. Join a free webinar with Living Beyond Breast Cancer for healthcare providers on April 10, from 12-1PM ET to learn more about the different biomarker tests available and how to effectively communicate results with your patients. Learn more and register at the link. https://lnkd.in/g6jK7Y8a #Agendia #illuminatingtumorbiology #livingbeyondbreastcancer
-
-
Join Agendia's Friday Evening ASBrS Industry Dinner Symposium on May 2nd from 7:30pm to 9pm PST in Bellagio rooms 3, 4, & 7. Dr. Jaime Alberty, and Dr. Beth DuPree will speak about MammaPrint and BluePrint for neoadjuvant treatment and surgical planning. You’ll also get the chance to review case studies and interact with our speakers in a Q&A session. Reserve your seat by clicking the link or scanning the QR code provided. We look forward to seeing you there! #Agendia #IlluminatingTumorBiology #BreastCancer #ASBRS2025 https://shorturl.at/bzoUf
-
-
Discover how the latest findings from the FLEX study can help you identify which HR+/HER2- early-stage breast cancer patients may respond to neoadjuvant chemotherapy using MammaPrint and BluePrint. Read the study by Dr. O'Shaughnessy to learn more! #Agendia #IlluminatingTumorBiology #BreastCancer https://lnkd.in/gpZEnsVM
-
Agendia转发了
Have you heard about the new findings from the MINDACT (EORTC 10041/BIG3-04) phase III trial? The findings reveal that the MammaPrint 70-gene signature can help guide chemotherapy decisions for invasive lobular carcinoma (ILC) patients. Key findings: ??16% of ILC cases are 70-gene high-risk with poor outcomes. ??Survival rates by 70-gene risk are similar for ILC and NST patients. ??No chemotherapy for high clinical, low genomic risk ILC patients should be considered. ??MammaPrint could facilitate chemotherapy decisions for patients diagnosed with ILC. Discover how MammaPrint could transform treatment decisions for ILC patients. ?? ??Read more: https://lnkd.in/edxSA_wm ? #BreastCancerResearch #ILC #MammaPrint #MINDACT #CancerResearch #Oncology #ClinicalTrials #EORTCBreast BIG against breast cancer
-
-
Agendia转发了
Have you heard about the new findings from the MINDACT (EORTC 10041/BIG3-04) phase III trial? The findings reveal that the MammaPrint 70-gene signature can help guide chemotherapy decisions for invasive lobular carcinoma (ILC) patients. Key findings: ??16% of ILC cases are 70-gene high-risk with poor outcomes. ??Survival rates by 70-gene risk are similar for ILC and NST patients. ??No chemotherapy for high clinical, low genomic risk ILC patients should be considered. ??MammaPrint could facilitate chemotherapy decisions for patients diagnosed with ILC. Discover how MammaPrint could transform treatment decisions for ILC patients. ?? ??Read more: https://lnkd.in/edxSA_wm ? #BreastCancerResearch #ILC #MammaPrint #MINDACT #CancerResearch #Oncology #ClinicalTrials #EORTCBreast BIG against breast cancer
-